The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease
Abstract
Objectives: The inhibition of acetylcholinesterase (AChE), the key enzyme in the breakdown of acetylcholine, is currently the main pharmacological strategy available for Alzheimer's disease (AD). In this sense, many alkaloids isolated from natural sources, such as physostigmine, have been long recognized as acetyl- and butyrylcholinesterase (BChE) inhibitors. Since the approval of galantamine for the treatment of AD patients, the search for new anticholinesterase alkaloids has escalated, leading to promising candidates such as huperzine A. This review aims to summarize recent advances in current knowledge on alkaloids as AChE and BChE inhibitors, highlighting structure–activity relationship (SAR) and docking studies. Key findings: Natural alkaloids belonging to the steroidal/triterpenoidal, quinolizidine, isoquinoline and indole classes, mainly distributed within Buxaceae, Amaryllidaceae and Lycopodiaceae, are considered important sources of alkaloids with anti-enzymatic properties. Investigations into the possible SARs for some active compounds are based on molecular modelling studies, predicting the mode of interaction of the molecules with amino acid residues in the active site of the enzymes. Following this view, an increasing interest in achieving more potent and effective analogues makes alkaloids good chemical templates for the development of new cholinesterase inhibitors. Summary: The anticholinesterase activity of alkaloids, together with their structural diversity and physicochemical properties, makes them good candidate agents for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 8×
“Although the role of AChE in improving memory and cognition in patients with AD is well established, the search for inhibitors of BChE, acting in the CNS, should not be neglected, since this enzyme is also responsible for inactivating acetylcholine in the brain tissue, and its expression is increased in patients suffe…”
BackgroundInfluentialKalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Acetylcholinesterase inhibitors from plants
Mukherjee, P. K., Kumar, V., Mal, M., & Houghton, P. J. (2007) · Phytomedicine · doi:10.1016/j.phymed.2007.02.002 · Cited by 809
Acetylcholinesterase inhibitors from plants and fungi
Houghton, P. J., Ren, Y., & Howes, M.-J. (2006) · Natural Product Reports · doi:10.1039/b508966m · Cited by 584
Medicinal plants and Alzheimer’s disease: From ethnobotany to phytotherapy
Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. L. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772808 · Cited by 285
Davis, K. L., & Powchick, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90526-x · Cited by 177
Neuroprotective effects of huperzine A: New therapeutic targets for neurodegenerative disease
Zhang, H. Y., & Tang, X. C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.004 · Cited by 174
Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Conway, K., Baxter, E., Felsenstein, K., & Reitz, A. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033391649 · Cited by 40
Cited by
Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders
Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., & Li, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23247 · Cited by 351
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Amoah, S. K. S., Dalla Vecchia, M. T., Pedrini, B., Carnhelutti, G. L., Gonçalves, A. E., dos Santos, D. A., Biavatti, M. W., & de Souza, M. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.018 · Cited by 40
Guesmi, F., Bellamine, H., & Landoulsi, A. (2018) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0107 · Cited by 27
Metadata
- Authors
- Konrath, E. L., Passos, C. D. S., Klein-Júnior, L. C., & Henriques, A. T.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-01
- Volume
- 65
- Issue
- 12
- Pages
- 1701-1725
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W1602284078
- Cited by
- 217
- References
- 12
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.